|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Gilead: A Hold Despite Cancer Advance, Remdesivir, Dividend [Seeking Alpha, March 11, 2021]
Gilead Sciences Is A Buy Despite Flat 2020 Guidance [Seeking Alpha, February 12, 2020]
Earlier articles are below the summaries table.
William P. Meyers Analyst Conference summaries available:
| 2024 | |||
 |
|
|
|
| April 25, 2024 | Aug. 8, 2024 | Nov. 6, 2024 | |
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 |
| 2023 | |||
|
|
|
|
| April 27, 2023 | August 3, 2023 | Nov. 7, 2023 | Feb. 6, 2024 |
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 |
| 2022 | |||
|
|
|
|
| April 28, 2022 | August 2, 2022 | Oct. 27, 2022 | Feb. 2, 2023 |
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 |
| 2021 | |||
|
|
|
|
| April 29, 2021 | July 29, 2021 | Oct. 28, 2021 | Feb. 1, 2022 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 |
| 2020 | |||
|
|
|
|
| April 30, 2020 | July 30, 2020 | Oct. 28, 2020 | Feb. 4, 2021 |
| Q1 2020 | Q2 2020 | Q3 2020 | Q4 2020 |
| 2019 | |||
|
|
|
|
| May 2, 2019 | July 30, 2019 | Oct. 24, 2019 | Feb. 4, 2020 |
| Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 |
2018 |
|||
|
|
|
|
May 1, 2018 |
July 25, 2018 |
Oct. 25, 2018 |
Feb. 04, 2019 |
Q1 2018 |
Q2 2018 |
Q3 2018 |
Q4 2018 |
2017 |
|||
|
|
|
|
May 2, 2017 |
July 26, 2017 |
Oct. 26, 2017 |
February 6, 2018 |
Q1 2017 |
Q2 2017 |
Q3 2017 |
Q4 2017 |
2016 |
|||
|
|
|
|
04/28/2016 |
07/25/2016 |
11/01/2016 |
02/07/2016 |
Q1 2016 |
Q2 2016 |
Q3 2016 |
Q4 2016 |
2015 |
|||
|
|
|
|
04/30/2015 |
07/28/2015 |
10/27/2015 |
02/02/2016 |
Q1 2015 |
Q2 2015 |
Q3 2015 |
Q4 2015 |
2014 |
|||
|
|
|
|
04/22/2014 |
07/23/2014 |
10/28/2014 |
02/03/2015 |
Q1 2014 |
Q2 2014 |
Q3 2014 |
Q4 2014 |
2013 |
|||
|
|
|
|
05/02/2013 |
07/25/2013 |
10/29/2013 |
02/04/2014 |
Q1 2013 |
Q2 2013 |
Q3 2013 |
Q4 2013 |
2012 |
|||
|
|
|
|
04/26/2012 |
07/26/2012 |
10/23/2012 |
02/04/2013 |
Q1 2012 |
Q2 2012 |
Q3 2012 |
Q4 2012 |
2011 |
|||
|
|
|
|
04/20/2011 |
07/26/2011 |
10/27/2011 |
02/02/2012 |
Q1 2011 |
Q2 2011 |
Q3 2011 |
Q4 2011 |
2010 |
|||
|
|
|
|
4/20/2010 |
07/20/2010 |
10/19/2010 |
01/25/2011 |
Q1 2010 |
Q2 2010 |
Q3 2010 |
Q4 2010 |
2009 |
|||
|
|
|
|
04/21/2009 |
07/21/2009 |
10/20/2009 |
01/26/2010 |
Q1 2009 |
Q2 2009 |
Q3 2009 |
Q4 2009 |
2008 |
|||
|
|
|
|
04/16/2008 |
07/17/2008 |
10/16/2008 |
01/27/2009 |
Q1 2008 |
Q2 2008 |
Q3 2008 |
Q4 2008 |
2007 |
|||
|
|
|
|
01/23/2008 |
10/18/2007 |
7/19/2007 |
4/18/2007 |
Q4 2007 |
Q3 2007 |
Q2 2007 |
Q1 2007 |
Gilead Sciences Deal With Galapagos NV Should Be A Winner [Seeking Alpha, September 2, 2019]
Galapagos NV Osteoarthritis Drug Candidate Has Vast Potential Value [Seeking Alpha, August 26, 2019]
Gilead Sciences At The Filgotinib And Selonsertib Crossroads [Seeking Alpha, May 9, 2019]
Gilead Q2 Results Could Initiate A Rally [Seeking Alpha, July 9, 2018]
Gilead Sciences Going Down When It Should Go Up [Seeking Alpha, 12/8/2017]
Gilead Sciences Q1 2016 Key Insights [May 3, 2016 at Seeking Alpha]
Wider Reach Is Sought for Costly New Hepatitis C Treatments [Aug. 25, 2015, New York Times]
Gilead Sciences: P/E and Pipeline Beyond HCV [June 9, 2015 at Seeking Alpha]
Could GlaxoSmithKline Be a Better Investment Than Gilead? [September 17, 2014 at Seeking Alpha]
The Solid Gold Wonder Drug [September 2014 Scientific American]
Gilead Down on Merck-Idenix Deal, But Little to Fear [June 9, 2014 at Seeking Alpha]
FDA Approves Zydelig (idelalisib) for CLL, FL, and SLL [July 23, 2014 Gilead press release]
Gilead Sciences Hepatitis C Approval May Be Factored In [July 30, 2013]
Gilead Sciences Pipeline Remains Undervalued [December 3, 2012]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Gilead Sciences Looks for Hepatitis C Cure [April 29, 2012]
Gilead Sciences Readies Pipeline [July 27, 2011]
Gilead Sciences, Antivirals, and Tamiflu [January 26, 2011]
Gilead Sciences Rebuilds Pipeline Optimism [October 24, 2010]
Gilead Sciences (GILD) Q2 Outlook [July 6, 2009]
Gilead (GILD) Thrives Despite Downturn [October 21, 2008]
Aztreonam Lysine Rejected by FDA [September 20, 2008]
Gilead Should Rise on Penetration, Viread [September 10, 2008]
Gilead Preps for Atripla in Europe [January 24, 2008]
Choosing a Biotech Stock 2: Gilead [September 10, 2007]
Gilead is a biotechnology pharmaceutical company; products include Atripla, Truvada, and Sovaldi. So far it has specialized in anti-viral agents for HIV, Hepatitis B, and Hepatitis C as well as cancer and cardiovascular therapies.
Gilead Sciences Web site:
Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.
Copyright 2024 William P. Meyers